The increasing prevalence of autoimmune disorders, inflammatory diseases, and chronic immune-mediated conditions is driving substantial growth in the global interleukin inhibitors industry. Pharmaceutical companies are focusing on the development of advanced biologics and targeted therapies to improve treatment outcomes and reduce disease progression. Rising healthcare expenditure, increasing...

 According to a new report from Intel Market Research, the global Tocilizumab Biosimilars market was valued at USD 1.45 billion in 2025 and is projected to reach USD 3.18 billion by 2034, growing at a CAGR of 9.7% during the forecast period (2026-2034). This significant growth is driven by the increasing prevalence of autoimmune diseases, cost...